bivictrix therapeutics ceo on promising ovarian cancer data, aim delisting and future plans
Published 1 month ago • 617 plays • Length 4:23Download video MP4
Download video MP3
Similar videos
-
6:18
bivictrix therapeutics announce plans to list on aim this august
-
4:33
bivictrix therapeutics 'making cancer therapeutics exquisitely selective for target'
-
27:39
novel therapeutics in ovarian cancer: what to watch
-
1:00
biomarker research in ovarian cancer
-
3:48
targeted therapy in newly diagnosed advanced ovarian cancer
-
5:17
outlook for patients with high-risk ovarian cancer
-
1:56
target ovarian cancer - be connected
-
1:12
where is ovarian cancer treatment headed?
-
4:38
managing toxicities in ovarian cancer treatments
-
4:36
ovarian cancer: understanding treatment endpoints
-
7:57
brian czerniecki - 20mb062-cancer vaccine using novel esr1 derived peptides for neoantigen therapy
-
4:52
ovarian cancer decisions: treatment versus maintenance
-
2:03
prognosis after more than 3 lines of therapy in ovarian cancer
-
1:43
composite biomarkers predictive of palbociclib endocrine treatment benefit in early breast cancer
-
1:00:23
want to get away? considering treatment breaks in ovarian cancer
-
3:48
targeted therapies for patients with ovarian cancer who have brca-mutated tumors
-
1:59
eoc: maintenance therapy with parp inhibitors